# The Missing Men: HIV Treatment Scale-Up and Life Expectancy in Sub-Saharan Africa

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Tsai, Alexander C., and Mark J. Siedner. 2015. “The Missing Men: HIV Treatment Scale-Up and Life Expectancy in Sub-Saharan Africa.” PLoS Medicine 12 (11): e1001906. doi:10.1371/journal.pmed.1001906. http://dx.doi.org/10.1371/journal.pmed.1001906. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1371/journal.pmed.1001906                                                                                                                                                                                                                                                   |
| Citable link    | http://nrs.harvard.edu/urn-3:HUL.InstRepos:23993595                                                                                                                                                                                                                               |
| Terms of Use    | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA                                                                                                           |
The Missing Men: HIV Treatment Scale-Up and Life Expectancy in Sub-Saharan Africa

Alexander C. Tsai1,2,3*, Mark J. Siedner3,4

1 Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 2 Mbarara University of Science and Technology, Mbarara, Uganda, 3 Harvard Medical School, Boston, Massachusetts, United States of America, 4 Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America

* actsai@partners.org

Delivery of effective HIV antiretroviral therapy (ART) to the more than 6 million persons with HIV in South Africa is well underway, with early data on the impact of this massive public health effort demonstrating a reversal of the previous decade’s precipitous decline in population life expectancy [1]. Although South Africa’s age and sex disparities in HIV acquisition have traditionally been described as disadvantaging young women [2], accumulating evidence now suggests a reverse disparity: although HIV care is available to both men and women and is nominally free of charge, women are more likely to be tested for HIV, engage in pre-treatment care, initiate treatment earlier, stay on treatment, and survive [3–6]. To adopt the classic Eisenberg and Power [7] analogy of health care as current flowing through an electric circuit, the voltage drops along the entire circuit of HIV care, from HIV infection to AIDS-free survival, are larger for men compared with women (Fig 1). There are simply too many missing men.

In recent years, studies from South Africa [8], as well as Rwanda [9] and Uganda [10], have begun to demonstrate the cumulative impact of these voltage drops, which, in total, result in an approximately 10-year life expectancy gap between men and women initiating ART at 20 years of age (Fig 2). However, the findings of these studies should be interpreted in light of important limitations. First, they were based solely on data obtained from persons enrolled in HIV treatment programs. Poverty, food insecurity, HIV stigma, and geographic barriers still exert outsize influences on HIV testing, treatment, and retention in these settings [11–14], so it is unlikely that these enrollees are representative of the entire population of persons with HIV. Second, mortality had to be estimated among those lost to follow up [9,10]. Because persons in HIV treatment programs are much more likely to be lost to care than confirmed as dead [15,16], and because the vast majority of HIV-related mortality events go unreported [17], the mortality estimates in these studies are likely to be biased. Third, and perhaps most notably, none of these studies directly observed non-HIV mortality. Thus, while they were able to document trends in mortality among persons with HIV, they were unable to assess the extent to which these changes were related to HIV care or to unrelated secular trends in health and health behavior.

In this context, the research article by Jacob Bor and colleagues [18] that appears this week in PLOS Medicine provides new evidence of a widening gender gap in life expectancy, using data obtained from a general population sample in rural South Africa from 2001–2011, covering a period of coincident ART scale-up. By surveilling all persons in the region—whether HIV-negative, HIV-positive in care, or HIV-positive but not in care—and by using verbal autopsies to categorize mortality events that were recorded by the surveillance teams, this
study addresses some of the limitations of previous work. Subject to the assumption that mortality events were comprehensively observed and accurately categorized—which would be generically limiting for any study conducted in a country with less than complete registration of vital events [19]—Bor and colleagues [18] were not obligated to account for non-uptake of HIV testing, nor were they required to estimate mortality among those lost to care or to estimate non-HIV mortality. Their findings are summarized by the stark observation that life expectancy gains among women far outstripped the life expectancy gains among men, and that these gains were independent of both age and first recorded CD4+ T-lymphocyte cell count. Perhaps more telling than the near-doubling of the gender gap in life expectancy during the observation period are the relative benefits women received throughout the entire HIV care
HIV-related mortality rates were approximately 2-fold higher among men compared with women, whether prior to ART or during both early and long-term ART.

What could explain these findings? Certainly women’s differential access to HIV care during pregnancy might be partially responsible. South Africa’s successful program for preventing mother-to-child transmission largely requires HIV testing for all pregnant women and encourages ART initiation among those found to be HIV positive [20]. This institutional link to program entry could partially explain why more than half of HIV-related mortality events among men in 2007–2011 occurred during the pre-treatment period, compared with only one-third of HIV-related mortality events among women. However, because the lower HIV-related mortality rates among women persisted even after accounting for age, CD4 count, and ART initiation, clearly more data are needed to explain the widening gender gap in life expectancy. Other major contributions likely result from historically ingrained social forces (such as increased migratory needs resulting from apartheid) and differential patterns of health behavior [21–23]. Even in the absence of these crippling disadvantages, a gender gap in life expectancy may yet remain [24], but the data presented by Bor and colleagues [18] signal the urgent need to better understand this large and widening disparity in South Africa and elsewhere in sub-Saharan Africa.

What can be done to address this problem? Different types of interventions should be considered. Minimally, policies could be revised to “nudge” men into HIV care; for example, opt-out HIV testing among military service members could be mandated as part of annual examinations or after deployments, peacekeeping missions, or foreign trainings [25]. Home-based HIV counseling and testing can potentially provide a greater degree of privacy for men concerned about discrimination, or by providing convenience for men whose willingness to undergo testing is constrained by work obligations [26]. Similarly, workplace-based treatment programs [27] or alternative patient-centered care models [28] may help to retain men in care once treatment has been initiated. And finally, social marketing to emphasize collateral impacts—such as economic benefits for individuals and their households [29] or reduced risks of secondary transmission to domestic partners [30] and/or unborn children [31]—may provide additional impetus for testing and treatment. Of note, while these “gender sensitive” intervention strategies attempt to minimize the ways in which socially constructed gender roles in South Africa constrain men’s health behavior, they still leave intact a system of gender inequality that confers distinct health disadvantages for women while simultaneously marshaling other threats to the health of men. Truly “gender transformative” intervention strategies will need to understand men’s health behavior as being intimately tied to the same prevailing gender roles and norms of masculinity that produce violence against women, constraints on capital ownership, alcohol and substance abuse, and sexual risk taking [23]. Given the complexity of the problem, multipronged approaches will likely be needed. Certainly, the AIDS-free generation will remain a far-off mirage until men also receive the health benefits made possible through the mass provision of HIV treatment, which somehow remains out of reach for too many of them.

Author Contributions

Wrote the first draft of the manuscript: ACT. Contributed to the writing of the manuscript: ACT MJS. Agree with the manuscript’s results and conclusions: ACT MJS. Both authors have read, and confirm that they meet, ICMJE criteria for authorship.

References

1. Bor J, Herbst AJ, Newell ML, Barnighausen T (2013) Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 339: 961–965. doi: 10.1126/science.1230413 PMID: 23430655
2. Abdool Karim Q, Abdool Karim SS, Singh B, Short R, Ngxongo S (1992) Seroprevalence of HIV infection in rural South Africa. AIDS 6: 1535–1539. PMID: 1492937

3. Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, Holst H, et al. (2010) Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS 24 Suppl 1: S37–44. doi: 10.1097/01.aids.0000366081.91192.1c PMID: 20023438

4. Geng EH, Bwana MB, Muyindike W, Glidden DV, Bangsberg DR, Neillands TB, et al. (2013) Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr 63: e64–71. doi: 10.1097/QAI.0b013e31828a5a6 PMID: 23429504

5. Geng EH, Nash D, Kangabu A, Zhang Y, Braitstein P, Christopoulos KA, et al. (2010) Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep 7: 234–246. doi: 10.1007/s11990-010-0061-5 PMID: 20820972

6. Druyts E, Dybul M, Kanters S, Nachega J, Birungi J, Ford N, et al. (2013) Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS 27: 417–425. doi: 10.1097/QAI.OB.0b013e328359b89b PMID: 22948271

7. Eisenberg JM, Power EJ (2000) Transforming insurance coverage into quality health care: voltage drops from potential to delivered quality. JAMA 284: 2100–2107. PMID: 11042759

8. Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O, et al. (2013) Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 10: e1001418. doi: 10.1371/journal.pmed.1001418 PMID: 23585736

9. Naanzimana S, Remera E, Kanters S, Chan K, Forrest JI, Ford N, et al. (2015) Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. Lancet Glob Health 3: e169–e177. doi: 10.1016/S2214-109X(14)70364-X PMID: 25701995

10. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. (2011) Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 155: 209–216. doi: 10.7326/0003-4819-155-4-20110816-00358 PMID: 21768555

11. Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, et al. (2013) Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc 16: 18640. doi: 10.7448/IAS.16.3.18640 PMID: 24242258

12. Lankowski AJ, Siedner MJ, Bangsberg DR, Tsai AC (2014) Impact of geographic and transportation-related barriers on HIV outcomes in sub-Saharan Africa: a systematic review. AIDS Behav 18: 1199–1223. doi: 10.1007/s10461-014-0729-8 PMID: 24563115

13. Chimbindi N, Bor J, Newell ML, Tanser F, Baltusser R, Hontelez J, et al. (2015) Time and money: the true costs of health care utilization for patients receiving "free" HIV/tuberculosis care and treatment in rural KwaZulu-Natal. J Acquir Immune Defic Syndr 70: e52–60. doi: 10.1097/QAI.0000000000000728 PMID: 26371611

14. Weiser SD, Palar K, Frongillo EA, Tsai AC, Kumbakumba E, dePee S, et al. (2014) Longitudinal assessment of associations between food insecurity, antiretroviral adherence and HIV treatment outcomes in rural Uganda. AIDS 28: 115–120. doi: 10.1097/01.aids.0000433238.93986.35 PMID: 23939234

15. Geng EH, Emenyounu N, Bwana MB, Glidden DV, Martin JN (2008) Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. J Am Med Assoc 300: 506–507.

16. Geng EH, Bangsberg DR, Musinguzi N, Emenyounu N, Bwana MB, Yiannoutsos CT, et al. (2010) Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 53: 405–411. doi: 10.1097/QAI.0b013e3181b843f0 PMID: 19745753

17. Geng EH, Odeny TA, Lyamuya RE, Nakiwoggwa-Muwanga A, Diero L, Bwana M, et al. (2015) Estimation of mortality among HIV-infected people on antiretroviral treatment in east Africa: a sampling based approach in an observational, multisite, cohort study. Lancet HIV 2: e107–116. doi: 10.1016/S2214-109X(15)00002-8 PMID: 26424542

18. Bor J, Rosen S, Chimbindi N, Haber N, Herbst K, Mutevedzi T, et al. (2015) Mass HIV treatment and sex disparities in life expectancy: demographic surveillance in rural South Africa. PLoS Med 12: e1001905. doi: 10.1371/journal.pmed.1001905 PMID: 18029006

19. Mahapatra P, Shibuya K, Lopez AD, Coullare F, Notzon FC, Rao C, et al. (2007) Civil registration systems and vital statistics: successes and missed opportunities. Lancet 370: 1653–1663. PMID: 18029006

20. Goga AE, Dinh TH, Jackson DJ, Lombard C, Delaney KP, Puren A, et al. (2015) First population-level effectiveness evaluation of a national programme to prevent HIV transmission from mother to child,
21. Courtenay WH (2000) Constructions of masculinity and their influence on men’s well-being: a theory of gender and health. Soc Sci Med 50: 1385–1401. PMID: 10741575
22. Mills EJ, Beyrer C, Birungi J, Dybul MR (2012) Engaging men in prevention and care for HIV/AIDS in Africa. PLoS Med 9: e1001167. doi: 10.1371/journal.pmed.1001167 PMID: 22346735
23. Jewkes R, Morrell R (2010) Gender and sexuality: emerging perspectives from the heterosexual epidemic in South Africa and implications for HIV risk and prevention. J Int AIDS Soc 13: 6. doi: 10.1186/1758-2652-13-6 PMID: 20181124
24. Oeppen J, Vaupel JW (2002) Demography. Broken limits to life expectancy. Science 296: 1029–1031. PMID: 12004104
25. Thomas AG, Grillo MP, Djibo DA, Hale B, Shaffer RA (2014) Military HIV policy assessment in sub-Saharan Africa. Mil Med 179: 773–777. doi: 10.7205/MILMED-D-13-00495 PMID: 25003863
26. Sabapathy K, Van den Bergh R, Fidler S, Hayes R, Ford N (2012) Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med 9: e1001351. doi: 10.1371/journal.pmed.1001351 PMID: 23226107
27. Meyer-Rath G, Pienaar J, Brink B, van Zyl A, Muirhead D, Grant A, et al. (2015) The impact of company-level ART provision to a mining workforce in South Africa: a cost-benefit analysis. PLoS Med 12: e1001869. doi: 10.1371/journal.pmed.1001869 PMID: 26327271
28. Decroo T, Telfer B, Blot M, Maikere J, Dezembro S, Cumba LI, et al. (2011) Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr 56: e39–44. doi: 10.1097/QAI.0b013e3182055138 PMID: 21084990
29. Tsai AC, Bangsberg DR, Weiser SD (2013) Harnessing poverty alleviation to reduce the stigma of HIV in sub-Saharan Africa. PLoS Med 10: e1001557. doi: 10.1371/journal.pmed.1001557 PMID: 24319400
30. King R, Lifshay J, Nakayiwa S, Katuntu D, Lindkvist P, Bunnell R (2009) The virus stops with me: HIV-infected Ugandans’ motivations in preventing HIV transmission. Soc Sci Med 68: 749–757. doi: 10.1016/j.socsci.med.2008.11.008 PMID: 19101063
31. Matthews LT, Crankshaw T, Giddy J, Kaida A, Smit JA, Ware NC, et al. (2013) Reproductive decision-making and periconception practices among HIV-positive men and women attending HIV services in Durban, South Africa. AIDS Behav 17: 461–470. doi: 10.1007/s10461-011-0068-y PMID: 22038045